Next-Gen Obesity Drugs Rival Bariatric Surgery With 15–25% Weight Loss

Obesity affects hundreds of millions globally and carries serious risks including cardiovascular disease, metabolic dysfunction, and premature death. For decades, meaningful pharmacological intervention remained elusive — until now. A growing understanding of the gut-brain axis and how gastroenteropancreatic hormones regulate appetite has fueled a wave of highly effective new drugs.

This 2025 review by Rubio-Herrera and Mera-Carreiro from Hospital Clínico San Carlos in Madrid synthesizes the current landscape of obesity pharmacotherapy. The authors examine drugs already on the market alongside those in active clinical trials, evaluating both efficacy and safety across a spectrum of agent classes.

GLP-1 receptor agonists — including weekly injectable semaglutide and the first approved daily oral formulation — achieve 15–17% body weight reduction with a favorable safety profile. Tirzepatide, a dual GLP-1/GIP receptor agonist, raises the ceiling further, producing up to 22.5% weight loss at its highest doses, edging toward surgical outcomes. On the horizon, triple-hormone combinations like retatrutide (GLP-1/GIP/glucagon) and cagrisema (cagrilintide plus semaglutide) are expected to match or exceed tirzepatide's results while also improving cardiometabolic markers.

The clinical implications are profound. Patients who previously faced surgery as their only path to significant weight loss now have pharmacological options in the same efficacy range. This is particularly relevant for individuals who are not surgical candidates or who prefer a non-invasive approach.

However, challenges remain. Long-term adherence is difficult, weight regain upon discontinuation is common, and access and cost are significant barriers. The review acknowledges these as central concerns for both patients and clinicians navigating this new treatment era. Lifestyle modification remains a necessary foundation alongside any pharmacological approach.